Citations (8)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Xiushuai Dong, Gang Lu, Xianwei Su, Jie Liu, Xi Chen, Yaoyao Tian, Yuying Chang, Lianjie Wang, Wei Wang & Jin Zhou. (2021) Identification of key miRNA signature and pathways involved in multiple myeloma by integrated bioinformatics analysis. Hematology 26:1, pages 976-984.
Read now
Read now
Xiaoping Liu, Jiarui Chen, Yuncen A He, Xiangyu Meng, Kaili Li, Colin K He & Shangqin Liu. (2017) Comparing efficacy and survivals of initial treatments for elderly patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials. OncoTargets and Therapy 10, pages 121-128.
Read now
Read now
Runzhe Chen, Xiaoping Zhang, Chong Gao, Chengxin Luan, Yujie Wang & Baoan Chen. (2017) Treatment and prognostic factors for survival in newly diagnosed multiple myeloma patients with bortezomib and dexamethasone regimen: a single Chinese center retrospective study. Cancer Management and Research 9, pages 373-380.
Read now
Read now
Articles from other publishers (5)
Na Zhao, Chunxia Qu, Yan Yang, Huihui Li, Yueyue Li, Hongbo Zhu & Zhiguo Long. (2023) Identification of a cholesterol metabolism-related prognostic signature for multiple myeloma. Scientific Reports 13:1.
Crossref
Crossref
Andrzej Jakubowiak, Saad Z. Usmani, Amrita Krishnan, Sagar Lonial, Raymond L. Comenzo, Jianping Wang, Carla de Boer, William Deraedt, Brendan M. Weiss, Jordan M. Schecter & Ajai Chari. (2021) Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 21:10, pages 701-710.
Crossref
Crossref
Pieter Sonneveld, María‐Victoria Mateos, Adrian Alegre, Thierry Facon, Cyrille Hulin, Mahmoud Hashim, Talitha Vincken, Tobias Kampfenkel, Sarah Cote, Jianming He, Annette Lam & Philippe Moreau. (2020) Matching‐adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible. eJHaem 1:2, pages 481-488.
Crossref
Crossref
Adrián Alegre, Javier de la Rubia, Anna Sureda Balari, Cristina Encinas Rodríguez, Alexia Suárez, María Jesús Blanchard, Joan Bargay Lleonart, Paula Rodríguez-Otero, Andrés Insunza, Luis Palomera, María Jesús Peñarrubia, Rafael Ríos-Tamayo, Luis Felipe Casado Montero, Marta Sonia González, Anna Potamianou, Catherine Couturier, Huiling Pei, Henar Hevia, Iordanis Milionis, Maren Gaudig & María-Victoria Mateos. (2020) Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma. HemaSphere 4:3, pages e380.
Crossref
Crossref
Xiao-Ping Liu, Xiao-Hong Yin, Xiang-Yu Meng, Xin-Hui Yan, Fan Wang & Li He. (2019) Development and Validation of a 9-Gene Prognostic Signature in Patients With Multiple Myeloma. Frontiers in Oncology 8.
Crossref
Crossref